中国药物警戒 ›› 2022, Vol. 19 ›› Issue (4): 432-435.
DOI: 10.19803/j.1672-8629.2022.04.19

• 安全与合理用药 • 上一篇    下一篇

Solriamfetol上市后真实世界不良反应研究

陈添玉1, 陈琪莹2, 张月珍1,*   

  1. 1泉州医学高等专科学校,福建 泉州 362011;
    2福建医科大学附属第二医院,福建 泉州 362000
  • 收稿日期:2020-06-15 出版日期:2022-04-15 发布日期:2022-04-15
  • 通讯作者: *张月珍,女,本科,副教授,医学循证与医学教育。E-mail：499368300@qq.com
  • 作者简介:陈添玉,女,硕士,医学循证与医学教育。
  • 基金资助:
    泉州医学高等专科学校科研项目（XJS1625）

Adverse reactions of solriamfetol after listing based on real world data

CHEN Tianyu1, CHEN Qiying2, ZHANG Yuezhen1,*   

  1. 1Quanzhou Medical College, Quanzhou Fujian 362011, China;
    2The Second Affiliated Hospital of Fujian Medical University, Quanzhou Fujian 362000, China
  • Received:2020-06-15 Online:2022-04-15 Published:2022-04-15

PDF (PC)

153

摘要： 目的 利用美国食品药品监督管理局药物不良事件报告系统（FAERS）检索solriamfetol上市后的不良反应报告,挖掘和分析该药的不良反应,以期为临床合理用药提供参考。方法 检索FAERS系统中2019年1月1日至2020年3月31日的solriamfetol不良反应报告数据,使用MYSQL软件对数据进行整理分析。结果 以solriamfetol为首要怀疑药品的不良反应报告122份,其中严重药品不良反应14份。累及系统-器官分类主要为：精神疾病、神经系统疾病、心脏疾病、呼吸道、胸部和纵隔腔疾病等,不良反应类型发生频率前10位为焦虑/紧张不安、失眠、感觉异常、胸痛、心动过速、自杀意念/自我伤害、干扰注意力、头晕、头痛、乏力。已知的报告者以消费者为主,发生不良反应的患者主要为女性,平均年龄为（31.95±15.26）岁,主要集中于18~45岁之间,适应证主要为嗜睡症,剂量以150 mg·d-1为多,83.33%的患者用药时间<1个月即出现不良反应。结论 Solriamfetol在临床应用过程中应加予关注,严格把握用药指征,做好用药宣教,加强用药监护,注意用药安全。

关键词: solriamfetol, 美国食品药品监督管理局药物不良事件报告系统, 药品不良反应

Abstract: Objective To analyze ADR induced by solriamfetol after listing via the FAERS (the US Food and Drug Administration Adverse Event Reporting System) so as to provide reference for clinical rational drug use. Methods The data on adverse reaction reports of solriamfetol submitted to the FAERS between January 1, 2019 and March 31, 2020 was retrieved and analyzed by MYSQL software. Results There were 122 ADR reports with solriamfetol as the primary suspected drug, 14 of which involved severe ADR. The main symptoms were psychiatric disorders, nervous system disorders, cardiac disorders, respiratory disorders, thoracic and mediastinal disorders. The top ten types of adverse reactions were anxiety, insomnia, paraesthesia, chest pain, sinus tachycardia, suicidal ideation, disturbance in attention, dizziness, headache and fatigue. Most of the people who reported discomfort were consumers, and the most of the patients with adverse reactions were female, with an average age of (31.95 ±15.26) years. Narcolepsy was the main manifestation, and the dose of 150 mg·d-1 was the most common. 83.33% of the patients developed adverse reactions after less than one month of medication. Conclusion The analysis of the incidence of adverse reactions after the listing of solriamfetol by means suggests that we should pay more attention to this drug in the process of clinical application, keep in mind the indications of drug use and try every means available to ensure the safety of this drug.

Key words: solriamfetol, FAERS, adverse drug reaction

中图分类号: